Undecimal raises $18M to move siRNA delivery beyond the liver

Co-founded by Yaniv Erlich and Shaul Ilan, the Eleven Therapeutics spinout will use the round to advance its DELiveri platform and renovascular programs.

By · Published · Updated

Primary source: Ctech

Why it matters

Undecimal is betting that better delivery can make siRNA useful in tissues beyond the liver. Its $18 million round funds a focused test of whether DELiveri can turn that bottleneck into a repeatable drug-discovery capability.

Undecimal raises $18M to move siRNA delivery beyond the liver — Co-founded by Yaniv Erlich and Shaul Ilan, the Eleven Therapeutics spinout will use the round to advance its DELiveri platform and renovascular programs.

Undecimal Bio announced an $18 million Seed round on October 13th to develop delivery methods for small interfering RNA medicines beyond the liver, where the class has made its clearest therapeutic progress. The financing was co-led by 4BIO Capital and IQ Capital, with Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures and Saras Capital participating, according to the…

Reader comments

Conversation for this story loads after sign-in.